Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Viridian Therapeutics Inc VRDN

Healthcare Biotechnology
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.


NDAQ:VRDN - Post by User

Viridian Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson Sep 13, 2024 11:31am
24 Views
Post# 36222329

VRDN Price Target Alert: $44.00. Issued by RBC Capital

VRDN Price Target Alert: $44.00. Issued by RBC Capital
News; $VRDN VRDN Price Target Alert: $44.00. Issued by RBC Capital2024-09-13 09:00:07 ET Gregory Renza from RBC Capital issued a price target of $44.00 for VRDN on 2024-09-13 07:52:00. The adjusted price target was set to $44.00. At the time of the announcement, VRDN was trading at $20.7. The overall price target consensus is at $37.08...VRDN - VRDN Price Target Alert: $44.00. Issued by RBC Capital

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities